LabGenius
LabGenius is a UK-based AI biotech that uses its proprietary EVA platform, combining machine learning with automated experimentation, to discover and optimize therapeutic antibodies for solid tumors and inflammation, serving major pharmaceutical partners (Sanofi, LG Chem) via licensing and co-development while advancing an internal pipeline led by LGTX-101.
- Company typePrivate
- Founded2012
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What LabGenius does
LabGenius is a UK-based, venture-backed biotechnology company that develops therapeutic antibodies using a proprietary AI-driven discovery engine called EVA. The platform combines machine learning with high-throughput automated experimentation in iterative design-build-test-learn cycles to identify and co-optimize complex antibody candidates — particularly multispecifics — across multiple properties simultaneously, a problem the company identifies as non-intuitive for conventional discovery methods. The firm maintains an internal pipeline focused on selectivity-enhanced antibodies for solid tumors, with lead asset LGTX-101, an AI-designed Nectin-4 x CD3 T-cell engager that has demonstrated greater than 90% tumor growth inhibition at 0.1 mg/kg in preclinical studies and is slated for presentation at AACR 2026. LabGenius claims its platform can compress the typical five-year antibody development timeline by approximately 50%.
The company's commercial model is a hybrid platform-plus-pipeline structure. It licenses the EVA platform to major pharmaceutical partners through multi-year research, option, and license agreements — including an ongoing collaboration with Sanofi focused on NANOBODY therapeutics for inflammation (expanded in December 2025 after a successful 2021 first collaboration) and a June 2026 agreement with LG Chem covering tumour-targeting multispecific antibodies with undisclosed upfront, early milestones, and potential triple-digit million clinical/regulatory/commercial milestones plus royalties. Revenue is generated through licensing upfronts, research funding, and contingent milestone payments; no commercial product revenue exists and pricing is not publicly disclosed. The company is headquartered in London, operates with 51-100 employees, and is backed by a syndicate including M Ventures, Atomico, Kindred Capital, Lux Capital, Obvious Ventures, Octopus Ventures, and LG Innovation Ventures, following a $44.5M financing round in May 2024.
LabGenius firmographics
Firmographics- Name
- LabGenius
- Legal name
- LabGenius Limited
- Website
- https://labgeniustx.com/
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- LabGenius is a UK-based AI biotech that uses its proprietary EVA platform, combining machine learning with automated experimentation, to discover and optimize therapeutic antibodies for solid tumors and inflammation, serving major pharmaceutical partners (Sanofi, LG Chem) via licensing and co-development while advancing an internal pipeline led by LGTX-101.
- Ownership category
- akta.pro rank
LabGenius industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where LabGenius is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
LabGenius business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Licensing & Research Collaborations: LabGenius licenses its EVA platform to pharmaceutical companies, receiving upfront payments, research funding, and potential milestones. Deal with LG Chem includes undisclosed upfront payment, early milestones, and potential triple-digit million clinical, regulatory, and commercial milestones plus royalties on net sales.
- Collaborative Development Revenue: Revenue from co-development partnerships including milestone payments tied to research, preclinical, clinical, regulatory, and commercial achievements. Sanofi collaboration focuses on antibody optimization for inflammation targets.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
LabGenius product offering
Product offeringCore offering
LabGenius operates the EVA™ platform, an AI/ML-driven discovery engine that combines machine learning with automated high-throughput experimentation in an iterative design-build-test-learn cycle to identify and co-optimise complex therapeutic antibodies across multiple properties. The company leverages this platform to develop its own internal pipeline of selectivity-enhanced antibody therapeutics for solid tumours (e.g., LGTX-101) and licenses the platform to pharmaceutical partners (Sanofi, LG Chem) for collaborative drug discovery programs.
Product overview
LabGenius is a UK-based AI biotechnology company offering a unified platform-plus-pipeline architecture. The core product is the EVA™ platform, an AI/ML-driven antibody discovery engine that combines machine learning with automated experimentation using an iterative design-build-test-learn cycle. The company leverages EVA to develop its internal pipeline of selectivity-enhanced antibody therapeutics for solid tumors, including the lead program LGTX-101, a Nectin-4 x CD3 T-cell engager. LabGenius also provides its platform as a service to pharmaceutical partners through collaborations with Sanofi and LG Chem.
Differentiator
Problem solved
Functional benefit
Products and services
- EVA™ Platform Highly automated AI-driven discovery engine that uses machine learning combined with high-throughput experimentation in an iterative design-build-test-learn cycle to rapidly identify and co-optimise complex therapeutic antibodies across multiple key properties. Licensed to pharmaceutical partners for collaborative drug discovery and used internally to develop the company's own pipeline of selectivity-enhanced antibody therapeutics for solid tumours.
- LGTX-101 AI-designed Nectin-4 x CD3 T-cell engager for the treatment of solid tumours, demonstrating robust T-cell activation and tumour growth inhibition in preclinical studies. Part of LabGenius's internal pipeline of selectivity-enhanced antibody therapeutics.
Quantifiable outcome
- Aims to reduce typical 5-year antibody development timeline by approximately 50%
- +3 more outcomes
Companies that use LabGenius
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
LabGenius technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
LabGenius partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- LG ChemcoreMulti-year research collaboration, option and licensing agreement to develop AI/ML-designed tumour-targeting antibodies using LabGenius's EVA™ platform. LG Chem will fund all research and development activities. LabGenius will receive an undisclosed upfront payment and potential early milestones, with potential triple-digit million clinical, regulatory, and commercial milestones plus royalties on net sales if LG Chem exercises its option. The collaboration aims to develop next-generation multispecific antibodies targeting solid tumour antigens across multiple difficult-to-treat cancer types.
- SanoficoreSecond collaboration with Sanofi for AI/ML-driven antibody optimization, focusing on NANOBODY® therapeutics for multiple inflammation targets. The partnership leverages LabGenius's EVA platform with an iterative design-build-test-learn cycle. Their previous 2021 collaboration demonstrated significant results with the 10 most enhanced NANOBODY variants achieving up to seven times the desired effect while maintaining the original molecule's potency.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
LabGenius competitors and assessment
Company assessmentDirect peers
- Absci: Public AI-driven antibody discovery company combining generative AI with high-throughput wet-lab capabilities. Most direct comparable to LabGenius in AI antibody design platform and pharma partnership model.
- BigHat Biosciences: ML-guided antibody engineering platform with integrated wet lab for design-build-test-learn cycles. Closely overlaps with EVA's multispecific antibody optimization focus.
- Generate Biomedicines: Generative AI biology platform developing de novo protein therapeutics across modalities including antibodies. Competes with LabGenius for pharma AI antibody partnerships and pipeline assets.
- Cradle Bio: AI platform for protein design and engineering serving biologics developers. Comparable in offering ML-based protein optimization services to pharma partners.
- Antiverse: UK-based AI antibody design company focused on difficult targets including GPCRs and ion channels. Geographic peer and overlapping platform offering for antibody discovery.
- Isogenica: UK-based antibody discovery company using proprietary technology to engineer VHH/single-domain antibodies. Direct peer in UK antibody engineering market with multispecific and NANOBODY®-adjacent capabilities.
Broad incumbents
- AbCellera: Public antibody discovery platform with established pharma partnerships and clinical-stage pipeline. A larger, more mature incumbent operating in the same antibody discovery space.
- Recursion Pharmaceuticals: Public AI-driven drug discovery platform combining high-throughput experimentation with ML. Broader scope than LabGenius (small molecules plus biologics) but operates adjacent AI/automation thesis.
- Ginkgo Bioworks: Large-scale synthetic biology platform with cell engineering and protein capabilities. Overlaps with LabGenius in using automated biological experimentation and AI to engineer biological systems.
Emerging players
- Adaptyv Biosystems: Automated protein engineering platform using high-throughput experimentation and ML. Comparable in wet-lab automation and design-build-test-learn methodology.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
LabGenius social profiles
Digital presenceLabGenius financial estimates
Financial estimateRevenue estimate
Valuation estimate
LabGenius leadership team
Management profileNumber of profiles
Profiles4 records
LabGenius funding detail
Funding detailFunding overview
Funding rounds6 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LabGenius M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LabGenius
What does LabGenius do?
LabGenius operates the EVA™ platform, an AI/ML-driven discovery engine that combines machine learning with automated high-throughput experimentation in an iterative design-build-test-learn cycle to identify and co-optimise complex therapeutic antibodies across multiple properties. The company leverages this platform to develop its own internal pipeline of selectivity-enhanced antibody therapeutics for solid tumours (e.g., LGTX-101) and licenses the platform to pharmaceutical partners (Sanofi, LG Chem) for collaborative drug discovery programs.
Is LabGenius a public or private company?
LabGenius is a private company. It is classified as venture growth investor backed and is currently operating.
When was LabGenius founded?
LabGenius was founded in 2012. It employs 51 to 100 people.
Where is LabGenius based?
LabGenius is headquartered in London, United Kingdom, in the Europe region.
How does LabGenius make money?
Two revenue lines are on record. Platform Licensing & Research Collaborations are the primary driver. The others are collaborative Development Revenue.
Who are LabGenius's main competitors?
Direct peers on record are Absci, BigHat Biosciences, Generate Biomedicines, Cradle Bio, Antiverse and Isogenica. Broad incumbents are AbCellera, Recursion Pharmaceuticals and Ginkgo Bioworks. Adaptyv Biosystems is listed as an emerging player.
Does LabGenius have an API?
No public API is recorded for LabGenius.
What industry is LabGenius in?
LabGenius's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.